A process for the preparation of fluorinated compounds having at least one OSF.sub.5 group, said method comprising the step of reacting SOF.sub.4 with a fluorinated 3- or 4-membered cyclic ether in the presence of a fluoride catalyst.

The present invention provides compounds according to Formula I as described herein, and their use for inhibiting the lysine gingipain protease (Kgp) from the bacterium Porphyromonas gingivalis. Also described are gingipain activity probe compounds and methods for assaying gingipain activity are also described, as well as methods for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease.

The present invention provides compounds according to Formula I as described herein, and their use for inhibiting the lysine gingipain protease (Kgp) from the bacterium Porphyromonas gingivalis. Also described are gingipain activity probe compounds and methods for assaying gingipain activity are also described, as well as methods for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease.

Provided herein is a process and intermediates for the preparation of a compound of formula (I): ##STR00001##
or a pharmaceutically acceptable salt thereof, using cyanamide in the reaction.

Disclosed are a series of malonamide derivatives having a chemical structure(I), their synthesis, and evaluation of their bioactivities against bacterial cell, bacterial-infected C.elegans and mice.

Disclosed are a series of malonamide derivatives having a chemical structure(I), their synthesis, and evaluation of their bioactivities against bacterial cell, bacterial-infected C.elegans and mice.

A process for the preparation of fluorinated compounds having at least one OSF.sub.5 group, said method comprising the step of reacting SOF.sub.4 with a fluorinated 3- or 4-membered cyclic ether in the presence of a fluoride catalyst.

A process for the preparation of fluorinated compounds having at least one OSF.sub.5 group, said method comprising the step of reacting SOF.sub.4 with a fluorinated 3- or 4-membered cyclic ether in the presence of a fluoride catalyst.

The present invention relates to novel biguanide derivatives including their pharmaceutically acceptable salts. The invention also relates processes for the preparation of, intermediates used in the preparation of, pharmaceutical compositions containing and the uses of such compounds in treating disorders such as diabetes.

The present invention relates to novel biguanide derivatives including their pharmaceutically acceptable salts. The invention also relates processes for the preparation of, intermediates used in the preparation of, pharmaceutical compositions containing and the uses of such compounds in treating disorders such as diabetes.